Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4.
This report describes a patient with metastatic malignant melanoma treated with recombinant human interleukin 4 who developed vitiligo and severe Graves' Disease after therapy. The patient has experienced complete remission of melanoma for 49+ months. The association of antitumor response, vitiligo and thyroid disorders is reviewed.
Weiss
G R
GR
Department of Medicine/Medical Oncology, University of Texas Health Science Center at San Antonio, 78284 USA.
Fehrenkamp
S H
SH
Tokaz
L K
LK
Sunderland
M C
MC
D000328:Adult; D005260:Female; D006111:Graves Disease / Q000139:chemically induced*; D006801:Humans; D015847:Interleukin-4 / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy; D014820:Vitiligo / Q000139:chemically induced*
D011994:Recombinant Proteins; D015847:Interleukin-4